Condition: Pancreas Adenocarcinoma · Sponsor: Capital Health System, Inc
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
This description comes directly from the study's public registry record.
Shirnett Williamson, MD · 609-303-4244 · swilliamson@capitalhealth.org
Always discuss trial participation with your own doctor first.
| Capital Health Medical Center-Hopewell | Pennington, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04998552